Vigilancia activa en cáncer de próstata

Abr 12, 2016 // by uromurcia // Novedades // No Comments

Viernes 29 de abril de 2016
Hospital General Universitario Reina Sofía
Área de Docencia. Planta 0 – Aula 1

Dr. J. Rubio Briones
Jefe del Servicio de Urología
Instituto Valenciano de Urología

Descargar programa (JPG)

• Twitter • StumbleUpon • Digg • Delicious • Facebook

Comments are closed.

Noticias

PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff 3 febrero, 2025 Elena Castro, David Lorente, David Olmos
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life 3 febrero, 2025 Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, Massimo Lazzeri
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma 3 febrero, 2025 Jens Bedke, Yasmin Abu Ghanem, Laurence Albiges, Stephanie Bonn, Riccardo Campi, Umberto Capitanio, Saeed Dabestani, Milan Hora, Tobias Klatte, Teele Kuusk, Lars Lund, Lorenzo Marconi, Carlotta Palumbo, Geraldine Pignot, Thomas Powles, Maxine Tran, Alessandro Volpe, Axel Bex
Editorial Board 1 febrero, 2025
Contents 1 febrero, 2025
Platinum Hall of Fame 1 febrero, 2025
Congress Calendar 1 febrero, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial 30 enero, 2025 Johann S. de Bono, Meng He, Zhen Shi, Malgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher Sweeney
Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives 30 enero, 2025 Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner
The Cost of Bladder Cancer: What Can Be Done? 28 enero, 2025 Arnulf Stenzl